MOTS-c, explained.
Mitochondrial open reading frame of the 12S rRNA-c. Research, safety questions, and treatment context.
The form
Pharmacy catalog form
The routine
No dependable human wellness schedule is established by this research.
The evidence
Animal treatment research · human observations
Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- Backed by FDA advisers, awaiting final rule
FDA advisers voted 7 to 5 on July 23, 2026 to allow compounding, after reviewing it for obesity and osteoporosis. Not compoundable until the final rule.
- At Goodmorrow
- Waitlist open
What it is
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described in 2015. In mice it improved insulin sensitivity and protected against weight gain on a high-fat diet.
What the evidence shows
Human evidence is early. There are small studies measuring natural MOTS-c levels in people, and very little on giving it as a treatment. The FDA reviewed it for obesity and osteoporosis.
How Goodmorrow handles it
If it becomes lawful, MOTS-c is a candidate for our GLP-1 Plus program. It won't replace medication with years of trial data behind it.
Stacks that include it
- Longevity stack: mots-c, epitalon and nad+
- GLP-1 Plus: our program for what the medication doesn't fix on its own
Follow updates about MOTS-c
Join the update list. This does not reserve a treatment or mean that future availability is assured.
Questions people ask
Does MOTS-c cause weight loss?
It did in mice. Nobody has shown it in a proper human trial. For weight loss that's been proven in people, GLP-1 medication is the standard.
Sources
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
- Research publicationThe Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Cell Metabolism, 2015
Good days ahead.
Join the opening list for appointment updates.